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Abstract
Background—Primary vesicoureteral reflux (PVUR) is the most common malformation of the 
kidney and urinary tract and reflux nephropathy is a major cause of chronic kidney disease in 
children. Recently, we reported mutations in tenascin XB (TNXB) as a cause of PVUR with joint 
hypermobility.
Methods—To define the role of rare variants in tenascin genes in the etiology of PVUR, we 
screened a cohort of patients with familial PVUR (FPVUR) and non-familial PVUR (NFPVUR) 
for rare missense variants in TNXB and tenascin C (TNC) genes after excluding mutations in 
ROBO2 and SOX17.
Results—We identified 134 individuals from 112 families with PVUR, we excluded two 
families with mutations in ROBO2. We found rare missense variants in TNXB in the remaining 
110 families comprising of 5/55 (9%) of families with FPVUR and 2/55 (4%) of NFPVUR. There 
were no differences in high-grade reflux, or renal parenchymal scarring between patients with and 
without TNXB variants. All patients with TNXB rare variants that were tested exhibited joint 
hypermobility. Overall we were able to identify causes of FPVUR in 7/57 (12%) families (9% in 
TNXB and 3% in ROBO2).
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Conclusions—In conclusion, a rare missense variant in TNXB in combination with a positive 
family history of VUR and joint hypermobility may represent a non-invasive method to diagnose 
PVUR and warrants further evaluation in other cohorts.
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Introduction
Primary vesicoureteral reflux (PVUR) is the retrograde flow of urine from the bladder into 
the upper urinary tract due to an abnormal ureterovesical junction [1-2]. It is the most 
common congenital anomaly of the kidneys and urinary tract (CAKUT) in children and it is 
also the most important risk factor for pyelonephritis2. The prevalence of PVUR in children 
is estimated to be 1-2% [3], but this is likely an underestimate because of phenotype 
heterogeneity and the lack of non-invasive diagnostic tools. In the pediatric age group, 
untreated PVUR is the single most important risk factor for renal parenchymal scarring 
(RPS) [1-2]. RPS due to PVUR (reflux nephropathy) is a major cause of end stage kidney 
disease requiring dialysis and kidney transplantation in children [4]. Although the 
pathogenesis of PVUR has not been fully elucidated, it is believed to be a developmental 
anomaly due to a defect in the reciprocal signaling interaction between metanephric 
mesenchyme and the ureteric bud during kidney development5. This interaction is controlled 
by a variety of genes during development. However, the entire repertoire of genes involved 
remains unknown [5]. Familial aggregation of PVUR has been reported in different studies, 
however few loci have been reported for PVUR and the genetic causes of familial PVUR are 
unknown in a large proportion of cases [6-8]. The variable expression of the disease often 
makes case ascertainment difficult and complex. In addition, the gold standard for 
diagnosing PVUR is a voiding cystourethrogram (VCUG), which requires catheterization of 
the child and radiation exposure, both undesirable interventions. Thus, ascertainment of 
large pedigrees with enough power for genome-wide linkage studies (GWLS) is often 
impossible. It is therefore not surprising that most of the loci that have been reported in the 
literature are from relatively small pedigrees, yielding findings that are inconclusive. We 
recently reported segregating mutations in the TNXB gene in a large kindred with PVUR and 
joint hypermobility [9]. The tenascin genes are a class of extracellular matrix proteins with a 
relatively similar structure comprising N-terminal assembly and C-terminal fibrinogen-like 
domains, epidermal growth factor (EGF)-like repeats, and fibronectin III domains [10-12]. 
These fibronectin domains control cell adhesion and migration during development [13].
The main objective of this study is to define the disease burden due to rare variants in TNXB 
and TNC (encoding for tenascin XB and tenascin C respectively) in a cohort of children with 
PVUR and define the relationship between rare variants in tenascin genes, PVUR severity, 
and joint hypermobility. We screened 110 families with familial or non-familial PVUR for 
rare variants (minor allele frequency <0.01) in TNXB and TNC genes and obtained clinical 
data including reflux grade and joint hypermobility score using the Beighton criteria14. We 
found rare missense variants in the TNXB gene in in 5/55 (9%) families with PVUR and 
2/55 (4%) individuals with non-familial PVUR. We did not find any segregating rare 
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variants in TNC. All the rare variants in TNXB were predicted to be damaging by at least one 
in silico prediction software program. All three individuals with rare TNXB variants who had 
formal joint examination were found to have significant joint hypermobility. Rare variants in 
TNXB are responsible for PVUR in 9% of families with familial PVUR and 4% of 
individuals with non-familial PVUR. These findings demonstrate that rare variants in TNXB 
and joint hypermobility may serve as a disease marker in familial PVUR and further 
reinforces the importance of genes encoding for extra cellular matrix proteins in the etiology 
and pathogenesis of PVUR.
Materials and Methods
Clinical Ascertainment
Institutional review board approval was obtained from Duke University Medical Center 
(Durham, NC). We obtained informed consent from parents and assent from children 
participating in the study. Study subjects were classified as previously described9. Briefly, 
study subjects were considered affected if they had VUR on voiding cystourethrogram 
(VCUG). Supportive evidence included history of recurrent urinary tract infection (UTI) and 
abnormal findings on renal ultrasonography. Unaffected individuals are those with no 
detectable VUR on screening VCUG performed as part of routine clinical care or if they 
were un-related married individuals in the family. Individuals classified as unknown are 
those with history of UTI but with no radiological investigations. We defined familial VUR 
as presence of at least two individuals with radiologically confirmed VUR in the same 
family.
Mutation Analysis
Genomic DNA was extracted from whole blood or saliva using standard methods. Mutation 
analysis was carried out by sequencing of both strands of all exons of TNXB, TNC, ROBO2 
and SOX17 using exon-flanking primers; primer sequences are listed in Supplementary 
Table 1. All sequences were analyzed with the Sequencher software (Gene Codes Corp, Ann 
Arbor, Michigan).
Stratification of Variants and in silico prediction of impact of missense changes
All missense variants with minor allele frequency <0.01 were subjected to further analyses. 
In silico prediction of impact of amino acid substitution was determined using the SIFT and 
Polyphen 2 software [15-16]. The impact of amino acid change on secondary structure of the 
protein was assessed by the I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) housed at the University of Michigan, Ann Arbor, USA.
Joint Examination for Hypermobility
Joint examinations for hypermobility were carried out using the Beighton hypermobility 
score [14]. The examiners (CER and SE) were blinded to the detailed clinical and genotype 
data.
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Data Analysis
The clinical data and frequency of rare missense variants in TNXB, TNC, ROBO2 and 
SOX17 were compared between the familial and non-familial group. All categorical data 
were compared by the χ2 test and Fisher’s exact test where indicated and p value <0.05 was 
considered significant.
Results
Clinical Data
We identified 134 individuals with PVUR; 79 individuals from 57 families were presumed 
to have familial VUR because there were two or more affected individuals in the family. 
The study population was predominantly Caucasian, with 74/79 (94%) of patients in the 
familial group and 48/55 (87%) of patients in the non-familial group self-identified as 
Caucasian. The majority 102/134 (76%) of the cohort were female. There was no significant 
difference in age at diagnosis between familial and non-familial PVUR patients (Table 1). 
Bilateral disease, distribution of reflux grades and presence of renal parenchymal scarring 
(RPS) on DMSA scan were similar between the familial and the non-familial groups (Table 
2). Severe PVUR (VUR grade > 3) was present in 31/79 (39%) of the familial group and 
was similar in frequency to the non-familial group 14/55 or 26% (Fisher’s exact test, p = 
0.14).
Screening for mutations in ROBO2 and SOX17
Since mutations in ROBO2 and SOX17 have previously been associated with congenital 
anomalies of the kidney (CAKUT) and isolated VUR [17-21], we screened the cohort for 
mutations in these genes and identified two families with segregating mutations in ROBO2 
(Table 3, Supplementary Figures 1 and 2 ) and one individual with a rare variant in SOX17. 
The two mutations found in ROBO2 are novel; they segregate with disease in the two 
families; they are not present in any public database, and both mutations are predicted to be 
damaging by in silico prediction software [15-16]. The pathogenicity of the SOX17 variant 
is unclear. We excluded individuals with ROBO2 mutations from the tenascin genes studies.
Screening for rare variants in TNXB and TNC
Familial VUR—We found six segregating heterozygous rare variants in TNXB in 5/55 (9%) 
of families with familial VUR who did not carry mutations in ROBO2 or SOX17 
(Supplementary Figures 1 and 2). We have previously reported two of these variants {c.
9770C>T (T3257I) and c.3991G>A (G1331R) in families 6606 and 6952 respectively} [9]. 
All the TNXB variants were annotated using the transcript ENST00000375244 
(Supplementary Figure 3). We found the rare variants in all the seven affected individuals 
screened from the three new families (Supplementary Figure 2). All the variants caused non-
conservative amino acid changes, and the amino acid changes were predicted to be 
damaging by at least one in silico prediction software. Three of the six variants in the 
FPVUR families are not listed in dbSNP, 1000 Genomes or NHLBI Exome Variant Server 
database. The other three variants have low minor allele frequency between 0.000 and 
0.0002 in at least 6,000 chromosomes. Furthermore, we did not find any of the variants in at 
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least 200 in-house ethnicity matched control chromosomes (Table 3). Interestingly, in one 
family (34324) we found two segregating heterozygous variants. Both variants are inherited 
in-cis from one of the parents. Four out of the six variants are located in the fibronectin III 
domains or linker regions between the fibronectin domains. Modeling one of the novel rare 
variant D3743N using the I-TASSER software (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) results in perturbation of the secondary structure of TNXB fibronectin III domain 
28 encoded by the exon carrying this rare variant (C-scores 0.15-0.19) (Figure 2). The 
phenotype associated with families with rare variants in TNXB gene is described in Table 4. 
We did not find segregating variants in TNC in any of the families studied.
Non-Familial VUR—Since we were not certain about the pathogenicity of the SOX17 
variant found in one individual with non-familial VUR, we screened all the 55 individuals 
with non-familial PVUR for rare variants in tenascin genes. We found rare variants (MAF: 
0.008, 0.0005) in TNXB in 2/55 (4%) of patients in this cohort. Similar to the familial cohort, 
the two variants were predicted to be damaging by in silico modeling (Table 3).
Joint Hypermobility in TNXB Rare Variants
We have previously reported that VUR co-segregates with joint hypermobility in a family 
with TNXB mutation [9]. To provide further evidence that the rare variants identified by us 
are likely to be pathogenic, we performed joint hypermobility testing on three individuals 
with rare variants in TNXB. All three individuals met the criteria for joint hypermobility with 
Beighton score of ≥4 (Table 3).
Discussion
PVUR is the most important risk factor for pyelonephritis and renal parenchymal scarring 
(RPS) in the pediatric age group [2]. Unlike other CAKUT, the genetic causes of PVUR are 
unknown in most cases [1-3, 22]. Mutations in ROBO2 and SOX17 have been reported as 
causes of isolated PVUR [17-21], and more recently we reported mutations in TNXB as a 
cause of PVUR [9]. In the present study, we performed mutation analysis in ROBO2, 
SOX17, TNXB and TNC in a cohort of patients with familial and sporadic PVUR. We found 
that rare variants in TNXB and ROBO2 account for 12% (9% TNXB and 3% ROBO2) of all 
cases of familial PVUR in this cohort and rare variants in TNXB for 4% of non-familial 
PVUR. Thus based on this modest cohort, rare variants in TNXB appeared to be the most 
common cause of autosomal dominant PVUR. Overall, we were able to identify a genetic 
cause of PVUR in 7/57 (12%) of families with familial PVUR. This is similar to 7% 
(47/650) in a cohort of 650 families with CAKUT reported by Hwang et al [21]. In their 
study, participants were screened for mutations in 17 known dominant genes that have been 
associated with CAKUT in both humans and animal models [19]. It should be noted that the 
panel of 17 genes in the Hwang study did not include TNXB. We did not find differences in 
bilateral disease, high-grade reflux, and RPS between patients with familial and non-familial 
diseases. The reason for this is unknown, but it may be due to the limited sample size of the 
present cohort. In addition, we did not have access to detailed prospective data on history of 
recurrent UTI, therapy and other factors that may influence outcome in PVUR in all the 
patients in our cohort.
Elahi et al. Page 5
Pediatr Nephrol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Further analysis of the families with rare variants in TNXB demonstrated that the prevalence 
of bilateral disease and high-grade reflux is similar to the prevalence in the entire cohort. 
Most of the variants found in TNXB are likely to be pathogenic because they segregate with 
the disease. Some are not in any public database and have extremely low MAF in the 
general population. In addition, all are predicted to be damaging by at least one in silico 
prediction software. Furthermore, all the individuals with the TNXB variants who had joint 
mobility examination done have significant joint hypermobility as assessed by Beighton 
score [14].
TNXB belongs to a family of large extracellular matrix proteins that is characterized by N-
terminal assembly domains, EGF-like repeats, multiple fibronectin III domains and a C-
terminal fibrinogen-like domain [9-13]. TNXB is expressed in kidneys and the urinary tract 
during development and it is highly expressed at a critical period when the ureterovesical 
junction (UVJ) is being formed [9]. We did not find any specific clustering of the variants in 
any exons or domains (Figure 1); however the majority of the variants (5/8) are located in 
the fibronectin III domains or linker regions between the fibronectin domains. The 
mechanism by which variants in TNXB cause PVUR has not been elucidated. However, we 
have shown in previous studies that fibroblast cell lines from an individual with T3257I 
missense mutation in TNXB displayed reduced cell motility in response to platelet derived 
growth factor and reduced expression of phosphorylated focal adhesion kinase suggesting 
persistent and enhanced cell adhesion and defective disassembly of focal adhesion [9]. 
Future studies will address the mechanisms by which the variants may cause defective 
formation of the UVJ during development.
We did not find any possible disease-causing variants in >80% of individuals with familial 
PVUR, thus further confirming that PVUR is genetically heterogeneous. There is significant 
need for further studies to identify other genetic causes of PVUR in order to develop a 
robust molecular diagnosis platform for PVUR. The clinical implications of our findings 
suggest that the presence of PVUR and joint hypermobility in a child presenting in clinic 
may warrant screening for rare missense variants in TNXB and other extracellular matrix 
protein genes in order to make a molecular diagnosis. If a pathogenic variant is identified in 
the index child presenting with PVUR, screening for rare missense variants in TNXB in 
asymptomatic family members may be enough to make a presumptive diagnosis of VUR.
In conclusion, familial PVUR is due to rare variants in TNXB and ROBO2 in 12% of all 
families with familial PVUR studied in this cohort. If the findings in this study are 
confirmed in an independent cohort, rare missense variants in TNXB and clinical findings 
such as joint hypermobility may represent a non-invasive diagnostic tool for PVUR.
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Figure 1. Rare missense variants in TNXB found in patients with PVUR
Exons of TNXB gene (filled boxes) and protein domains (filled oval). Five of the eight 
missense variants are located in the fibronectin III or linker regions between the domains.
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Figure 2. Missense variant D3743N in TNXB resulted in perturbation of 28th fibronectin III 
domain of the protein
I-TASSER was used to model the structure of TNXB FnIII domain 28. The model was 
predicted to be reliable with a robust C-scores 0.15-0.19. Residue D3743 (in red) is 
predicted to reside in fibronectin domain 28. Structural modeling of the 28th fibronectin III 
domain containing the D3743N variant (highlighted in red) resulted in, perturbation of the 
secondary structure of the protein.
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Table 1
Demographics of 134 individuals with Primary VUR
Parameters Familial VUR#
n=79
Non Familial VUR
n=55
Age at diagnosis median (range)* 1.9 (0.02-10) 1.56 (0.1-6.0)
Race (%)
      Caucasian 94 87
      African American 4 7
      Asian 1 2
      Hispanic 1 4
Gender (%)
      Female 76 76
      Male 24 24
*
Information available on 117 individuals, 67 familial and 50 non familial,
#VUR: Vesico ureteric reflux
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Table 2
Clinical Phenotype of 134 patients with Primary VUR
Parameters Familial VUR#
n=79
Non Familial VUR
n=55
Fisher’s
exact p
VUR Highest Grade (%)
Grade 1 6 5
Grade 2 27 29
Grade 3 28 40
Grade 4 21 20
Grade 5 18 6 0.24
VUR > grade 3 any side (%) 39 26 0.14
Bilateral VUR (%) 56 66 0.29
Renal parenchymal scarring (%)* 53 44 0.62
*
Information available on 65 individuals (38 familial and 27 non-familial)
#VUR: Vesico ureteric reflux
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Table 3
Rare Variants in TNXB and ROBO2 in Families with PVUR
Family
number
Familial
Y/N
Gene Variant rs number MAF
(EVS)
Frequency
in house
controls
Polyphen
score#
Sift
score*
6606+ Y TNXB c.9770C>T (T3257I) NA 0 0 0.99 0.15
6952+ Y TNXB c.3991G>A (G1331R) NA 0 0 1.0 0
34324 Y TNXB c.11227G>A (D3743N) NA 0 0 1.0 0.2
34324 Y TNXB c.11581G>A (A3861T) rs201121030 0 0 0.94 0.07
34439 Y TNXB c.211G>T (V71L) rs201922477 0.0002 0 0.98 0
34222 Y TNXB c.619G>A (G207S) rs139154852 0.0001 0 0.99 0
34334 N TNXB c.113G>A (R38Q) rs149502087 0.008 0 0.98 0
6866 N TNXB c.8740G>A (G2914S) rs200708257 0.0005 0 1.0 0.04
6836 Y ROBO2 c.911 C>A (A304D) NA 0 0 0.99 0.01
34333 Y ROBO2 c.2200 G>A (E734K) NA 0 0 0.99 0.003
#Polyphen score range 0 – 1.0 with 1.0 most damaging
*SIFT score range 0 – 1.0 with 0 most damaging
+
The findings in Families 6606 and 6952 have previously been reported in reference 9.
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Table 4
Phenotype of Patients with PVUR and Rare Variants in TNXB
ID TNXB variants Sex Age
(yrs)
Bilateral
VUR
Y/N
VUR ≥
Grade 3
Y/N (Side)
Reflux
nephropathy
Y/N
Joint
hypermobility
Y/N
6606-01+ c.9770C>T (T3257I) F 4.0 N N Y Y
6606-132+ c.9770C>T (T3257I) F 0.5 N N N U
6606-103+ c.9770C>T (T3257I) F 1.0 Y Y (L) Y U
6952+ c.3991G>A (G1331R) F 6.0 N N Y U
c.11227G>A (D3743N)
34324-01 c.11581G>A (A3861T) M 0.3 Y Y (R&L) Y U
34439-01 c.211G>T (V71L) F 3.25 N N U Y
34439-100 c.211G>T (V71L) F 0.1 Y Y (R&L) U
34222 c.619G>A (G207S) F 3.0 Y Y (L) U U
34334 c.113G>A (R38Q) F 0.9 Y Y (R&L) U Y
6866 c.8740G>A (G2914S) F 0.5 N N N U
N= No, Y= Yes, U= Unknown, L=Left, R= Right, F= Female, M= Male
+
The findings in Families 6606 and 6952 have previously been reported in reference 9.
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